Skip to main content
SpringerLink
Log in

La chimiothérapie adjuvante. Quels sont les nouveaux standards ?

  • Conference paper
Cancer du sein

  • 242 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Fisher B, Ravdin RG, Alisman N RK et al. (1068) Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg 168: 337–56

    Article  Google Scholar 

  2. Bonnadonna G, Brusamolino E, Valagussa P et al. (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294: 405–10

    Article  Google Scholar 

  3. Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early Breast Cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339: 1–15, 71–85

    Google Scholar 

  4. Fisher B, Brown AM, Dimitov NV et al. (1990) Two months of doxorubicincyclophosphamide with and without interval reinduction compared with six months of cyclophosphamide-methotrexate-fluorouracil in positive node breast cancer patients with tamoxifen non responsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B 15. J Clin Oncol 8: 1483–96

    PubMed  CAS  Google Scholar 

  5. Fisher B, Jeong JH, Dignam J et al. (2001) Findings from recent National Surgery Adjuvant Breast and Bowel Project adjuvant studies in stage 1 breast cancer. J Natl Cancer Inst Monograph: 62–6

    Google Scholar 

  6. Levine MN, Bramwell VH, Pritchard KI et al. (1998) Randomized trial of intensive cyclophosphamide, epirubicin and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil in premenopausal women with node positive breast cancer. National Cancer Institute of Canda Clinical Trials Group. J Clin Oncol 16: 2651–8

    PubMed  CAS  Google Scholar 

  7. Bonneterre J, Roché H, Kerbrat P et al. (2004) Long term cardiac follow up in relapse-free patients after six courses of fluorouracil, Epirubicin, and cyclophosphamide with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French Adjuvant Study Group. J Clin Oncol 22:3070–37

    Article  PubMed  CAS  Google Scholar 

  8. Bonneterre J, Roché H, Kerbrat P et al. (2005) Epirubicin 100 mg/m2/cycle increases long term survival in adjuvant chemotherapy of patients with poor prognosis, node-positive, early breast cancer: 10 year follow-up results of the French Adjuvant Study Group 05 trial. J Clin Oncol, in press.

    Google Scholar 

  9. Early Breast cancer Trialists’ Cooperative group (2005) Effects of adjuvant chemotherapy and hormonal therapy on breast cancer recurrence and long term survival. The Lancet, in press.

    Google Scholar 

  10. Buzdar AU, Singletary SE, Valero V et al. (2002) Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 8: 1073–9

    PubMed  CAS  Google Scholar 

  11. Henderson IC, Berry DA, Demettri GD et al. (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node positive primary breast cancer. J Clin Oncol 21: 976–83

    Article  PubMed  CAS  Google Scholar 

  12. Mamounas EP, Bryant I, Lembersky BC et al. (2003) Paclitaxel following doxorubicin/cyclophosphamide as adjuvant chemotherapy for node positive breast cancer. Proc Am Soc Clin Oncol 22, abstr 12

    Google Scholar 

  13. Martin M, Pienkowski T, Mackey J et al. (2003) TAC improves DFS and OS over FAC in node positive early breast cancer patients. BCIRG01. In San Antonio Breast Cancer Symposium, Dec 3–6, 2003; San Antonio, TX, abstr 43

    Google Scholar 

  14. Jones SE, Savin MA, Asmar I et al. (2003) Three year results of a prospective randomized trial of adjuvant chemotherapy for patients with stageI-III operable, invasive breast cancer comparing four courses of doxorubicin/cyclophosphamide to four courses of docetaxel/cyclophosphamide. Proc A Soc Clin Oncol 22, abstr 59

    Google Scholar 

  15. Roché H, Fumoleau P, Spielmann M et al. (2004) Five year analysis of the PACS 01 trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. In San Antonio Breast Cancer Symposium, Dec 8–11, 2004; San Antonio, TX, abstr 27

    Google Scholar 

  16. Loesh D, Greco FA, O’Shaughnessy J et al. (2004) A randomized multicenter trial comparing regimens of doxorubicin+ cyclophosphamide followed by paclitaxel or doxorubicin+ paclitaxel followed by weekly paclitaxel as adjuvant therapy for patients with high risk breast cancer. In san Antonio Breast Cancer Symposium, Dec 8–11, 2004; San Antonio, TX, abstr 28

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service cancérologie-gynécologie, Centre Oscar-Lambret, Rue Frédéric-Combemale, 59020, Lille Cedex

    J. Bonneterre

Authors
  1. J. Bonneterre
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag France, Paris

About this paper

Cite this paper

Bonneterre, J. (2006). La chimiothérapie adjuvante. Quels sont les nouveaux standards ?. In: Cancer du sein. Springer, Paris. https://doi.org/10.1007/2-287-31109-2_24

Download citation

  • DOI: https://doi.org/10.1007/2-287-31109-2_24

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-25174-0

  • Online ISBN: 978-2-287-31109-3

Publish with us

Policies and ethics

Search

Navigation